We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Question FDA Thinking On ‘Subjective’ New Inspection Powers
Drugmakers Question FDA Thinking On ‘Subjective’ New Inspection Powers
October 4, 2013
The FDA’s interpretation of what constitutes delaying or denying an inspection is far too subjective, and highlights the need for an appeals process for pharma companies flagged as obstructionist, drugmakers say in comments.